Kai He

This publication record appears to combine work from multiple distinct researchers sharing the name Kai He, spanning cancer immunotherapy clinical trials (CAR-T cells, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy), Brucella infection immunology, and unrelated fields like plant genomics, water quality science, and geophysics. The clinical oncology thread focuses on developing and testing new cancer treatments—such as engineered T-cell therapies and antibody-based drugs—for cancers including lung cancer, sarcoma, and multiple myeloma. Because the topics are so varied and disconnected, prospective students should verify which specific research area and institutional affiliation this profile actually represents before drawing conclusions.

Publication counts have grown markedly since 2020, rising from roughly 1-2 papers per year earlier in the decade to a peak of 12 in 2025, though the yearly pattern is uneven, suggesting the record may blend outputs from multiple same-named authors.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026